Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.008|
|52 Week High||AU$0.007|
|52 Week Low||AU$0.016|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||-27.27%|
|3 Year Change||-84.91%|
|5 Year Change||-98.26%|
|Change since IPO||-99.95%|
Recent News & Updates
|MEB||AU Healthcare Services||AU Market|
Return vs Industry: MEB underperformed the Australian Healthcare Services industry which returned 39.9% over the past year.
Return vs Market: MEB underperformed the Australian Market which returned 21.1% over the past year.
Stable Share Price: MEB is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MEB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. It has a clinical trial agreement with MedBridge Healthcare LLC to support sleep analysis of depressive burden (SADB) trial.
Medibio Fundamentals Summary
|MEB fundamental statistics|
Is MEB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MEB income statement (TTM)|
|Cost of Revenue||AU$170.70k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.00082|
|Net Profit Margin||-117.57%|
How did MEB perform over the long term?See historical performance and comparison
Is Medibio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MEB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MEB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MEB is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: MEB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MEB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MEB is good value based on its PB Ratio (0.9x) compared to the AU Healthcare Services industry average (4.2x).
How is Medibio forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: MEB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEB's is expected to become profitable in the next 3 years.
Revenue vs Market: MEB's revenue (64.8% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: MEB's revenue (64.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEB's Return on Equity is forecast to be low in 3 years time (12.6%).
How has Medibio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEB is currently unprofitable.
Growing Profit Margin: MEB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MEB is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.
Accelerating Growth: Unable to compare MEB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: MEB has a negative Return on Equity (-9.06%), as it is currently unprofitable.
How is Medibio's financial position?
Financial Position Analysis
Short Term Liabilities: MEB's short term assets (A$2.7M) exceed its short term liabilities (A$963.7K).
Long Term Liabilities: MEB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MEB is debt free.
Reducing Debt: MEB has no debt compared to 5 years ago when its debt to equity ratio was 42.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MEB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MEB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year
What is Medibio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Claude Solitario is the Managing Director of Medibio Limited since January 9, 2020 and also serves its Chief Executive Officer. He has been Director at Medibio Ltd. since December 31, 2018.He served a...
CEO Compensation Analysis
Compensation vs Market: Claude's total compensation ($USD181.25K) is below average for companies of similar size in the Australian market ($USD303.55K).
Compensation vs Earnings: Claude's compensation has increased whilst the company is unprofitable.
Experienced Management: MEB's management team is considered experienced (2.9 years average tenure).
Experienced Board: MEB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.
Medibio Limited's employee growth, exchange listings and data sources
- Name: Medibio Limited
- Ticker: MEB
- Exchange: ASX
- Founded: 1987
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$14.360m
- Shares outstanding: 1.80b
- Website: https://medibio.com.au
- Medibio Limited
- 100 Albert Road
- Level 4
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:05|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.